Chapter 4

Cash and the Dividend

The fall lifted Pernod Ricard's cash and dividend yields, but not to the lines this framework uses. Reported free cash flow yields about 7.0% (8.4% on the group's recurring measure) and the dividend yields about 7.4% — both short of the ~10% reference. The €4.70 dividend, frozen since FY2023, is no longer covered by reported free cash flow and now absorbs about 65% of recurring profit against a ~50% policy. Leverage sits at 3.3x with no financial covenant, ample liquidity — and buybacks that stopped at the lows.

The yield rose, but not to the line

At €63.88, Pernod Ricard's roughly 252 million diluted shares carry a market value near €16.1bn [1]. Against that, FY2025 free cash flow of €1,133m as the company reports it — €1,348m on its recurring measure — puts the free-cash-flow yield at 7.0% to 8.4%, and the €4.70 dividend yields 7.4% [2].

Sources: market value derived from the FY2025 reported share count and the €63.88 price [3]; FCF and dividend from the FY2025 net-debt reconciliation [4]; net debt/EBITDA of 3.3x per company disclosure [5].

This is the first place the setup looks different from a textbook dislocation. In the classic version the price fall alone drives the free-cash-flow yield past 10%, because cash generation holds while the denominator collapses. Here the yield stalls in the 7% to 8% range because the numerator fell too: FY2025 reported free cash flow of €1,133m is down from €1,813m in FY2022 [6]. A cheaper price met a smaller cash flow, so the yield sits below the reference line rather than through it.

Why the cash flow is depressed

Pernod Ricard converts profit to cash more slowly than most consumer-staples peers because it must pre-fund years of maturing spirit — inventory stands at €8.4bn, and the group invests continuously in strategic inventories and distillation capacity. Both of those calls are discretionary in timing, and both were run hot through the boom.

Source: operating cash flow, capital expenditure and free cash flow derived from reported financials, FY2022–FY2025 [7].

Free cash flow troughed at about €1.0bn in FY2024, which management attributed directly to "an increase in planned investments in capex and maturing inventories" landing at the same time profit fell [8]. Capital expenditure rose from 4.7% of sales in FY2022 to 6.7% in FY2024 before easing to 6.1% in FY2025, and free cash flow recovered 18% to €1,133m as that spend began to normalize [9].

The direction from here is the more important point. Management has guided strategic investments below €900m in FY2026 and to no more than about €1bn medium-term, with cash conversion targeted at circa 80% and above and a €1bn efficiency programme through FY2029 [10]. Run those targets forward: if recurring net profit recovers toward the €2.0bn it posted in FY2024 and conversion reaches 80%, recurring free cash flow lands near €1.6bn — about a 10% yield on today's market value [11].

Source: reported and recurring FCF yields on FY2025 cash flow [12]; the normalized bar is illustrative — recurring net profit recovering to ~€2.0bn at ~80% cash conversion, derived from management's medium-term targets [13].

So the ~10% line is reachable, but only on a double recovery: the earnings base has to climb back toward FY2024 and cash conversion has to improve at the same time. Neither is delivered. The reading that fits the evidence is that this cash engine is pointed the right way — normalizing capex and inventory release cash even at flat profit — while sitting one recovery short of the yield the framework looks for. What would move it up is a return of recurring net profit toward €2bn with strategic investment held under €1bn; what would keep it stuck is a second year of falling profit that offsets the investment normalization.

The dividend: frozen, and now above policy

Pernod Ricard's stated policy is a payout of "circa. 50% of net profit from recurring operations, with the aim of increasing the dividend each year" [14]. It honored that policy on the way up — the dividend grew from €3.12 in FY2021 to €4.70 in FY2023, each year near a 50% payout. Then it froze. The board has held €4.70 for three consecutive years while recurring net profit per share fell from €9.11 to €7.26, so the payout ratio has climbed to about 65% [15].

Source: dividend per share and five-year dividend record [16]; recurring net profit per share FY2021–FY2023 [17] and FY2024–FY2025 [18].

Two facts sit in tension. On the coverage side, the dividend is not covered by reported cash: €1,201m paid against €1,133m of reported free cash flow is 0.94x, and FY2024 was worse at 0.80x — it clears only on the recurring measure, at 1.12x [19]. And measured against the company's own policy, the current €4.70 is about 30% above where a strict 50% payout on FY2025 recurring profit per share (€7.26) would put it — roughly €3.63 [20].

Against that, the dividend has genuine support. Reported free cash flow grew 18% in FY2025 even as profit fell, narrowing the coverage gap [21]. Liquidity is not the constraint (below). And management has repeatedly framed the flat payout as deliberate and policy-aligned rather than stretched — at the FY2024 results it proposed the dividend "flat versus last year of €4.70 per share, fully aligned with our financial policy" [22].

The honest read is that this is a covered-but-not-comfortable dividend, not the high-conviction, hard-to-cut payout a yield-led case needs. It is defensible today; it is not underwritten with high conviction. The condition that would force a cut is specific: a second leg down in recurring profit that pushes the payout well beyond policy, or pressure on the investment-grade rating that makes deleveraging the priority. Cutting €4.70 back to the ~€3.63 the policy implies would free roughly €270m a year — the single largest discretionary lever the group has left, now that buybacks are already near zero.

Leverage and the balance sheet

Net debt closed FY2025 at €10.7bn, or 3.3x EBITDA — up from 3.1x a year earlier [23]. That increase runs against management's FY2024 guidance that "our leverage ratio is to improve as reported profit from recurring operation growth normalizes" [24]. Profit did not normalize, so leverage drifted the wrong way.

The cost of that debt is rising as low-coupon bonds mature into a higher-rate market. Pernod Ricard's bond stack still carries coupons as low as 0.125% to 1.75% from 2019–2022 issuance, while new paper prices at 3.25% to 3.75% — the €800m issued in March 2025 pays 3.25% [25]. Reported financial expenses rose to €584m in FY2025 from €505m a year earlier [26], and management put the average cost of debt at 3.2% and climbing [27]. As the sub-1% bonds issued in the zero-rate years refinance at today's coupons, that charge keeps building — a structural drag on pre-tax profit, independent of the demand cycle.

What the balance sheet does provide is time. The group's bank and bond contracts carry no financial-leverage covenant — the credit agreements "do not include any covenants stipulating compliance with financial leverage ratio (e.g., net debt/EBITDA)" [28]. Liquidity is deep: €1.8bn of cash, an undrawn €2.1bn sustainability-linked revolving facility extended to April 2030, and a laddered maturity profile with no wall — the nearest maturities are a €600m bond due May 2026 and a $600m bond due June 2026, comfortably inside cash and the facility [29]. The group can outlast a multi-year downturn on liquidity. The binding constraint is not a covenant or a maturity — it is the investment-grade rating management lists as its first priority, which is what makes rising leverage, not a refinancing cliff, the thing to watch.

Self-help ran backwards

Ruchir's self-help test asks whether management is buying alongside a contrarian at the lows. Here the record runs the other way. Pernod Ricard repurchased and cancelled €752m of stock in FY2022 at an average price near €190, and its financial policy places buybacks last — "carrying out share buybacks when all three priorities above are fulfilled" [30]. At the FY2023 results the group guided a further "share buyback program of €500m to €800m in FY24" [31]. It then executed only €334m in FY2024 — below its own plan — and just €11m in FY2025, effectively stopping [32].

Source: number of listed shares at 30 June, FY2021–FY2023 [33] and FY2022–FY2025 [34].

The share count fell from about 262 million in FY2021 to 252 million in FY2025 — a roughly 4% reduction — but almost all of it was bought at prices between €126 and €218, at an average well above €160 [35]. The repurchases wound down exactly as the price collapsed toward €64, and the count is now essentially flat. For a contrarian, the mechanical consequence matters more than the optics: with buybacks stopped, there is no share-count tailwind quietly lifting per-share earnings above consensus, and management is not signalling, with its own cash, that it sees the market's error. That is the reverse of the self-help pattern the framework rewards.

The cash chapter therefore cuts against the friendlier reading of the price-versus-intrinsic gap the report turns on: the yields are real but below the reference lines, the dividend is covered only on the recurring measure and sits above policy, and the one form of self-help that would compound a contrarian's edge has been switched off at the bottom. None of that makes the dislocation undeserved — that verdict rests on demand, settled elsewhere — but it removes the free options a cleaner balance sheet and an aggressive buyer would have added.